2b antagonists. RU patent 2457842.
RussianPatents.com
 

Method of prevention and treatment of liver disease with application of receptor a2b antagonists. RU patent 2457842.
Method of prevention and treatment of liver disease with application of receptor a<sub>2b</sub> antagonists. RU patent 2457842.

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to field of medicine. Method of treatment and prevention of liver fibrosis includes peroral introduction to mammal of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione. Method of reducing hepatotoxic side effects of chemical therapy or radiotherapy includes peroral introduction to mammal who underwent such treatment of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl) -1,3,7-trihydropurine-2,6-dione.

EFFECT: application of claimed group of inventions is efficient for prevention and treatment of liver diseases.

6 dwg, 21 ex

 

 
IPC classes for russian patent Method of prevention and treatment of liver disease with application of receptor a2b antagonists. RU patent 2457842. (RU 2457842):

A61P1/16 - for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61K31/522 -
Another patents in same IPC classes:
Granule and method for making thereof / 2456980
Invention refers to pharmaceutics. A pharmaceutical granule is spherical or spheroidal and has volume density 0.6-1.3 g/ml and disintegration 0.5-5 minutes. Active pharmaceutical ingredients are preparations of Traditional Chinese Medicine, herbal preparations or their extracts with a nucleus made of an extract of Traditional Chinese Medicine or herbal preparations, and a pharmaceutically acceptable carrier. The content of the pharmaceutically acceptable carrier with respect to total granule weight makes 10-60 wt %. The granule diameter can be equal to 700-1500 mcm. The granule nucleus diameter can be equal to 200-750 mcm. The granule can be also coated with a layer of 2-5 wt % with respect of total granule weight. A method for making the granules consists in introducing initial granules into a layer of a fluidised material as an excipient; the active pharmaceutical ingredients are prepared in the form of a suspension or a solution of the viscosity controlled within 6.0-9.8 MPa·s with using a viscosity-control agent; then they are sprayed over a surface of the initial granule for making a finished granule.
Method for preventing and treating hepatic consequences of ischemia Method for preventing and treating hepatic consequences of ischemia / 2456678
Liver is resected in an animal experimentally. A pharmacological protection is presented by Mexicor and Serotonine Adipinate. On the operation day, 5% Mexicor is used in the form of intravenous slow stream introductions twice - 35 minutes before the operation in a dose of 5 mg/kg of weight and 11 hours after the first introduction in a dose of 7 mg/kg of weight. Serotonine Adipinate dissolved in 5 ml of isotonic solution NaCl is used in the form of intravenous slow stream introductions three times - 1 hour before the operation in a dose of 0.15 mg/kg of weight, 2 hours after the first introduction in a dose of 0.2 mg/kg of weight, 10 hours after the first introduction in a dose of 0.1 mg/kg of weight. During the postoperative period, Mexicor and Serotonine Adipinate are introduced for 8 days. Mexicor is introduced three times a day at 9 o'clock in a dose of 2.5 mg/kg of weight, at 15 o'clock in a dose of 1.5 mg/kg of weight, at 21 o'clock in a dose of 6 mg/kg of weight. Serotonine Adipinate is introduced twice a day - at 8 o'clock in a dose of 0.15 mg/kg of weight, at 17 o'clock in a dose of 0.1 mg/kg of weight.
Benzimidazole derivatives, based pharmaceutical composition and methods of using them Benzimidazole derivatives, based pharmaceutical composition and methods of using them / 2456276
Present invention refers to new benzimidazole derivatives of general formula (I) or to its pharmacologically acceptable salts wherein R1 represents a C6-aryl group which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), or a heterocyclic group which represents pyridyl, dihydrobenzofuranyl, 1,3-benzodioxolyl, tetrahydropyranyl, tetrahydrofuranyl which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), R2 represents a C1-C6 alkyl group, R3 represents a C6-aryl group which can be substituted by 1-2 groups optionally specified in a group of substitutes (a), Q represents a group represented by formula =CH-, or a nitrogen atom and a group of substitutes (a) represents a group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a carboxyl group, a C2-C7 alkylcarbonyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, an amino group, a 4-morpholinyl group and a di-C1-C6 alkyl)amino group. Also, the invention refers to a pharmaceutical composition based on a compound of formula (I), to a PPARγ activator/modulator based on the compound of formula (I), to using the compound of formula (I), to a method of reducing blood glucose, to a method of activating PPARγ, a method of treating and/or preventing said pathological conditions.
Method of preventing liver injury in formation of syndrome of combined dystrophic-degenerative changes of mesenchimal derivatives in case of local chronic inflammatory process and means for its realisation Method of preventing liver injury in formation of syndrome of combined dystrophic-degenerative changes of mesenchimal derivatives in case of local chronic inflammatory process and means for its realisation / 2455988
Claimed is means for prevention (prophylaxis) of liver injury in formation of syndrome of combined dystrophic-degenerative changes of mesenchimal derivatives in case of local chronic inflammatory process, located outside the liver (CDDCMD in case of LCIP located outside the liver), which represents hormone of pineal gland - melatonin and corresponding method of prevention (prophylaxis) of liver injury in formation of CDDCMD in case of LCIP.
Method of treating dyskinesia of gallbladder at background of chronic psycho-emotional stress Method of treating dyskinesia of gallbladder at background of chronic psycho-emotional stress / 2455970
Invention relates to medicine, namely to physiotherapy, gastroenterology. Method includes introduction of diet No5, internal intake of mineral water with the following carrying out transverse galvanisation of epigastrium area, general coniferous baths and impact with physical factor. As physical factor used is electromagnetic radiation of extremely high frequency (EHF). Impact is performed by broad-band noise emitter with frequency 40-63 GHz. Impact is performed on 3 and 4 projection zones in area of the right hypochondrium and on the area of sternum. Impact is performed daily, 10 minutes on each zone. Course includes 10-12 procedures.
Method for stimulating liver regeneration in fibrotic changes in experiment / 2455701
Under the conditions of modelling cirrhosis in experiment, the preparation EMBRYOBLASTE is introduced in liver tissue by means of an injector needle at the depth up to 0.1 cm. The preparation is introduced along a front surface of the liver, 2 injections in each lobe of the liver to form a papula. The volume of one injection makes 0.3 ml.
Use of xanthohumol and isoxanthohumol as active substance for preventing and/or controlling liver diseases Use of xanthohumol and isoxanthohumol as active substance for preventing and/or controlling liver diseases / 2454996
Group of inventions refers to medicine and aims at preventing and treating a liver diseases. What is used is xanthohumol of formula (I) or xanthohumol metabolite as an active substance for making a preparation for preventing and/or controlling the liver diseases caused by obesity and/or diabetes. The daily dose varies within 0.01 to 161 mg/kg of weight. The xanthohumol content in the composition makes 0.1 to 99 wt %.
New piperazine amide derivatives New piperazine amide derivatives / 2454412
Invention refers to new piperazine amide derivatives of formula wherein X represents N or CH; Y represents N or CH; R1 represents lower alkyl, phenyl, phenyl-lower alkyl wherein phenyl can be optionally substituted by 1-2 substitutes independently specified in a group consisting of halogen, lower alkyl; R2 represents lower alkyl, phenyl, naphthyl or heteroaryl specified in dimethylisoxazolyl, quinolinyl, thiophenyl or pyridinyl wherein phenyl or heteroaryl are optionally substituted by 1 substitute optionally specified in a group consisting of halogen, lower alkoxy group, fluor-lower alkyl, lower alkoxy-carbonyl and phenyl; R3 represents phenyl, pyridinyl or pyrazinyl wherein phenyl, pyridinyl or pyrazinyl are substituted by 1-2 substituted optionally specified in a group consisting of halogen, lower alkyl and fluor-lower alkyl; R4, R5, R6, R7, R8, R9, R10 and R11 independently represent hydrogen, as well as to their physiologically acceptable salts. These compounds are bound with LXR alpha and LXR beta, and are applicable as therapeutic agents for treatment and/or prevention of high lipid levels, high cholesterol levels, low HDL cholesterol, high LDL cholesterol, atherosclerotic diseases, diabetes, non insulin dependent diabetes mellitus, metabolic syndrome, dislipidemia, sepsis, inflammatory diseases, infectious diseases, skin diseases, colitis, pancreatitis, cholestasis, liver fibrosis, psoriasis, Alzheimer's disease, etc.
Hepatoprotector Hepatoprotector / 2454243
Invention refers to medicine and pharmacology, and concerns a hepatoprotector prepared of Amur maackia. The hepatoprotector representing Amur maackia extract which contains up to 70% of 7-O-[β-D-glucopyranosyl-(1→6)]-β-D-glucopyranoside genistein, pseudobaptigenine, formononetin, 5-methoxydaidzein and maackianine.
Method of treating patients with chronic noncalculous cholecystitis / 2451530
Invention refers to medicine, namely - to therapy, physiotherapy. A method involves electrophoresis of an area of right hypochondrium. Interstitial carnitine electrophoresis is applied. The area is exposed to sinusoidal modulated currents of modulation frequency 70 - 100 Hz, modulation percentage 25 - 50 %, and marking interval 2-3 seconds. Carnitine is prescribed orally 20-30 minutes before the beginning of the procedure in the form of 20 % aqueous solutions 3 g. The procedures are daily. The therapeutic course is 10 procedures.
1h-pyrrolo[3,4-b]quinoline-3,9(2h,4h)-diones exhibiting anti-tuberculosis activity and method for preparing them 1h-pyrrolo[3,4-b]quinoline-3,9(2h,4h)-diones exhibiting anti-tuberculosis activity and method for preparing them / 2457208
Present invention refers to organic chemistry, namely new 1H-pyrrolo[3,4-b]quinoline-3,9(2H, 4H)-dione derivatives of general formula 1
Method of predicting spasm of coronary arteries in patients with ischemic heart disease during transcutaneous surgery / 2446734
Invention relates to medicine, cardiology, and can be used for predicting spasm of coronary arteries in patients with ischemic heart disease during transcutaneous coronary surgery. For this purpose on empty stomach at room temperature initial indices of cheek mucosa and skin temperature are measured. After that difference of said values Δt1 is calculated. Xantinol nokotiniate in dose 0.3 g is introduced to patient. 15-20 minutes later temperature is remeasured in said points. After that their difference Δt2 is calculated. Temperature coefficient ΔT is calculated by formula: ΔT=Δt1-Δt2. If value ΔT is higher than 1, prognosis of intraoperative coronary spasm development is considered to be unlikely. If value ΔT is lower than 1, prognosis of intraoperative coronary spasm development is considered to be probable to a considerable extent.
Selective adenosine a<sub>2a</sub> receptor antagonists for preparing drug for atrial fibrillation Selective adenosine a2a receptor antagonists for preparing drug for atrial fibrillation / 2445099
What is offered is applying selective adenosine A2A receptor antagonists for preparing drugs for atrial fibrillation in mammals including a human. It has been found that adenosine A2A receptor of atrial cardiac myocytes is involved in pathological mechanisms underlying atrial fibrillation.
Method for making medicated wax matrix particles, extruder to be used for method and prolonged-release cilostazol containing medicine Method for making medicated wax matrix particles, extruder to be used for method and prolonged-release cilostazol containing medicine / 2443406
Invention relates to chemical-pharmaceutical industry. A medication is prepared at the following stages (i) and (ii): (i) supplying at least one medicine and at least one wax into an extruder which has a drum temperature and a mould temperature set higher than a melting point of at least one wax; and (ii) simultaneously melting and mixing at least one wax in the extruder to prepare the melted mixed medicine and wax, spraying the melted mixed medicine and wax into a gaseous medium having a temperature lower than the melting point of wax through a spraying nozzle immediately attached to the mould located at the top of the extruder drum, thereby granulating the mixture.
Valganciclovir powder / 2440118
Declared invention refers to chemical-pharmaceutical industry, and concerns new solid pharmaceutical dosage forms of valganciclovir hydrochloride for oral administration after reduced in water. These new pharmaceutical dosage forms are applicable for treating or controlling viruses, such as herpes virus or cytomegalovirus.
Method of treating degenerative-dystrophic musculoskeletal diseases and posttraumatic adhesive processes Method of treating degenerative-dystrophic musculoskeletal diseases and posttraumatic adhesive processes / 2436584
Invention refers to medicine, namely to traumatology and orthopaedics, and can be used for treating degenerative-dystrophic musculoskeletal diseases and posttraumatic adhesive processes. That is ensured by preparing a suspension of the following composition: the ointments Indometacin, Chondroxide, Essaven gel in proportions 1:1:1 mixed with the preparation Karipazim 50 mg dissolved in physiologic saline 5 ml, 2 % Trental and vitamin E solution 100 IU. The prepared suspension is introduced to the patient by phonophoresis within 5 minutes per a field. The therapeutic course is 15-20 procedures.
Method of treating ecomodified atopic dermatitis in children being residents of technogenic chemical environments Method of treating ecomodified atopic dermatitis in children being residents of technogenic chemical environments / 2436574
Invention refers to medicine, namely to dermatology and can be used for treating atopic dermatitis in children being residents of technogenic chemical environments with increased body biological environment contamination. This is ensured by standard background therapy together with intravenous drop-by-drop administration of cytoflavinum every day at 1 ml per 10 kg of child's body weight, dissolved in 150-200 ml of 0.9 % sodium chloride at 30-40 drops a minute for 3-7 days.
2-thyoxanthene derivatives having effect of mpo inhibitors 2-thyoxanthene derivatives having effect of mpo inhibitors / 2435772
Present invention refers to new 2-thyoxanthene derivatives, namely to a compound of formula or its pharmaceutically acceptable salt, representing: 3-(2-ethoxy-2-methylpropyl)-2-thyoxantene; 3 (2-propoxy-2-methylpropyl)-2-thyoxanteme; 3-(2-methoxy-2-methylpropyl)-2-thyoxantene; 3 (2-isopropoxyethyl)-2-thyoxantene; 3 (2-ethoxypropyl)-2-thyoxantene; 3 (2S-ethoxypropyl)-2-thyoxantene; 3-(2R-ethoxypropyl)-2-thyoxantene. Also, the invention refers to a pharmaceutical composition on the basis of the compound of formula I, to application of the compound of formula I in preparing a drug.
Pde inhibitors and their combinations for treatment of urologic disorders Pde inhibitors and their combinations for treatment of urologic disorders / 2435588
Claimed is application of vardenafil or its salt, hydrate or salt hydrate for preparation of pharmaceutical composition for treatment of disease from group of diseases, that includes syndrome of infravesical obstruction (SIVO), genitourinary disorders, which include syndrome of neurogenic urinary bladder (NUB), urinary incontinence (UI), such as mixed, acute, stress or incontinence caused by overfill, pain in pelvis, benign and malignant diseases of organs constituting genitourinary system in men and women, kidney diseases, such as acute and chronic renal failure, immunologically induced kidney diseases such as renal transplant rejection, lupus nephritis, kidney diseases caused by immune complexes, glomerulonephritis, nephritis, toxic nephropathy, and obstructive uropathies in mammals, as well as for treatment of neurogenic urinary bladder, superactive urinary bladder and intersticial cystitis and corresponding pharmaceutical compositions.
Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride / 2434870
Invention relates to novel crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride, hydrates and/or solvates (versions) thereof, for which characteristic powder diffraction patterns with radiation CuKα1 are given, with characteristic peaks expressed in values of d (Å). Said modifications can be used to treat neurological disorder. The invention also relates to pharmaceutical compositions (versions) which may additionally contain folate, separately or together with arginine in an effective amount. The folate is folic acid or tetrahydrofolate selected from tetrahydrofolic acid, 5,10-methylene-tetrahydrofolic acid, 10-formyl-tetrahydrofolic acid, 5-formyl-tetrahydrofolic acid or 5-methyl-tetrahydrofolic acid, or polyglutamate thereof or pharmaceutically acceptable salt thereof. The invention also relates to methods of producing (versions) said crystalline modifications. For example, the method of producing crystalline form A of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride involves dissolving (6R)-L-erythro-tetrahydrobiopterin dihydrochloride in water at ambient temperature, and (1) cooling the solution to a low temperature with solidification of the solution, and removing water at pressure ranging from 0.01 to 1 mbar, or (2) removing water from said aqueous solution by filtering and drying with evaporation of water, and extracting said crystalline form.
Synergistic inhibition of viral replication with long-chain hydrocarbons and nucleoside analogs Synergistic inhibition of viral replication with long-chain hydrocarbons and nucleoside analogs / 2251415
The present innovation deals with antiviral preparations that contain aliphatic alcohol C21-C28 in combination with either nucleoside or nucleotide analog or phosphoformic acid in pharmaceutically acceptable carrier. It is necessary to mention that n-docosanol is considered to be a preferable aliphatic alcohol. Concentration of aliphatic alcohol C21-C28 corresponds to 0.05% to 40% by weight. Concentration of either nucleoside or nucleotide analog or phosphoformic acid corresponds to 0.1% to 10% by weight. The innovation, also, deals with the ways to treat viral infections due to applying such compositions. Aliphatic alcohols C21-C28 synergistically intensify antiviral activity of nucleoside analogs directed against replication of several herpetic viruses and that of cow's pox.
© 2013-2014 RussianPatents.com